• Maria Del Pilar Estevez-Diz, Renata Colombo Bonadio, Vanessa Costa Miranda, and Jesus Paula Carvalho.
• Instituto do Cancer do Estado de Sao Paulo-Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo 01246-000 2, Brazil.
• Ecancermedicalscience. 2020 Jan 1; 14: 1060.

AbstractDuring the COVID-19 pandemic, health services worldwide are going through important adaptations to assist patients infected with COVID-19, at the same time as continuing to provide assistance to other potentially life-threatening diseases. Although patients with cancer may be at increased risk for severe events related to COVID-19 infection, their oncologic treatments frequently cannot be delayed for long periods without jeopardising oncologic outcomes. Considering this, a careful consideration for treatment management of different malignancies is required. Cervical cancer is concentrated mainly in low-middle income countries (LMICs), which face particular challenges during the COVID-19 pandemic due to the scarcity of health resources in many places. Although cervical cancer is the fourth cause of cancer death among women, it receives little attention from international Oncology societies and scientific research studies. In this review paper, we discuss the cervical cancer landscape and provide specialists recommendations for its management during the COVID-19 pandemic, particularly focused on LMICs' reality.© the authors; licensee ecancermedicalscience.

5 keywords...

hide…